Denali Advisors’s AbCellera Biologics ABCL Stock Holding History

Denali Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-87,600	Closed	-$661K	–	470
2023 Q1	$661K	Buy	+87,600	New	+$795K	0.27%	91

Other funds holding ABCL

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

FFVM

Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Denali Advisors's ABCL Position: Q2 2023 in Review

Denali Advisors sold out of AbCellera Biologics (ABCL) in Q2 2023, closing a stake of 87,600 shares — an estimated $661K sold.

Denali Advisors first reported a position in ABCL in Q1 2023 and held it in 1 quarter. The position peaked at $661K in Q1 2023. 169 funds tracked by Wall St. Rank hold ABCL as of Q2 2023.

Denali Advisors reported no remaining AbCellera Biologics position as of Q2 2023 after selling out during the quarter.
Denali Advisors sold 87,600 AbCellera Biologics shares in Q2 2023, an estimated $661K.
Denali Advisors first reported a position in AbCellera Biologics in Q1 2023 and held it in 1 quarter.
Denali Advisors's AbCellera Biologics position peaked at $661K in Q1 2023.
169 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2023.

Based on Denali Advisors's 13F filing for Q2 2023, filed 18 Jul 2023.